Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type iv hypersensitivity response and reduction of tumor growth factor beta-expressing t cells

dc.date.accessioned2016-12-05T15:36:50Z
dc.date.available2016-12-05T15:36:50Z
dc.date.created2016-12-05T15:36:50Z
dc.date.issued2009
dc.identifier0732-183X
dc.identifierhttp://hdl.handle.net/10533/142453
dc.identifier1060935
dc.identifierWOS:000263513000018
dc.languageeng
dc.publisherAMER SOC CLINICAL ONCOLOGY
dc.relationinfo:eu-repo/grantAgreement/Fondecyt/1060935
dc.relationinfo:eu-repo/semantics/dataset/hdl.handle.net/10533/93477
dc.relationinstname: Conicyt
dc.relationreponame: Repositorio Digital RI2.0
dc.relationinstname: Conicyt
dc.relationreponame: Repositorio Digital RI2.0
dc.rightsinfo:eu-repo/semantics/openAccess
dc.titleProlonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type iv hypersensitivity response and reduction of tumor growth factor beta-expressing t cells
dc.typeArticulo


Este ítem pertenece a la siguiente institución